Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Georgia Research Alliance | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The term 'hypersomnia' describes a group of symptoms that includes severe daytime sleepiness and sleeping long periods of time (more than 10 hours per night). Sometimes, hypersomnia is caused by a problem with the quality of sleep occurring at night, for instance when nighttime sleep is disrupted by frequent breathing pauses. In other cases, however, hypersomnia occurs even when nighttime sleep is of good quality. These cases of hypersomnia are presumed to be a symptom of brain dysfunction, and so are referred to as hypersomnias of central (i.e., brain) origin, or primary hypersomnias.
The causes of most of these primary hypersomnias are not known. However, our group has recently identified a problem with the major brain chemical responsible for sedation, known as GABA. In a subset of our hypersomnia patients, there is a naturally-occurring substance that causes the GABA receptor to be hyperactive. In essence, it is as though these patients are chronically medicated with Valium (or Xanax or alcohol, all substances that act through the GABA system), even though they do not take these medications.
Current treatment of central hypersomnias is limited. For the fraction of cases with narcolepsy, there are FDA-approved, available treatments. However, for the remainder of patients, there are no treatments approved by the FDA. They are usually treated with medications approved for narcolepsy, but sleep experts agree that these medications are often not effective for this group of patients.
Based on our understanding of the GABA abnormality in these patients, we evaluated whether flumazenil (an medication approved by the FDA for the treatment of overdose of GABA medications or the reversal of GABA-based anesthesia) would reverse the GABA abnormality in our patients. In a test tube model of this disease, flumazenil does in fact return the function of the GABA system to normal. The investigators have treated a few patients with flumazenil and most have felt that their hypersomnia symptoms improved with this treatment.
To determine whether flumazenil is truly beneficial for primary hypersomnia, this study will compare flumazenil to an inactive pill (the placebo). All subjects will receive both flumazenil and the placebo at different times, and their reaction times and symptoms will be compared on these two treatments to determine if one is superior. Currently, flumazenil can only be given through an injection into a vein (i.e., intravenously). This study will evaluate this intravenous dosing as well as a new form of flumazenil, which is taken as a lozenge to be dissolved under the tongue. If this study shows that flumazenil is more effective than placebo in the treatment of hypersomnia, it will identify a potential new therapy for this difficult-to-treat disorder.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo, then Flumazenil | Experimental | Subjects in this arm will first receive a day of placebo, then a day of sublingual flumazenil |
|
| Flumazenil, then Placebo | Experimental | Subjects in this group will first receive a day of sublingual flumazenil, then a day of placebo. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Flumazenil | Drug | Sublingual flumazenil |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Psychomotor Vigilance Task (PVT) Median Reaction Time | The PVT measures the reaction time to button press following the presentation of a visual stimulus, reported here as the median reaction time for multiple presentations during the 10 minute task. The measure used was the change in median reaction time from baseline to drug administration, where the median reaction time at each of the time points (below) was averaged to provide a single on-treatment value for median reaction time. The measure was then calculated as baseline value - treatment value, such that higher numbers denote improvement from baseline. | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) |
| Measure | Description | Time Frame |
|---|---|---|
| PVT Additional Measure #1, Change in Lapse Frequency | A PVT lapse is defined as a reaction time exceeding 500 msec following the presentation of a single stimulus, which are then summed for the entire 10 minute PVT testing period. The measure used was the change in the frequency of lapses from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lynn Marie Trotti, MD | Emory University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Emory Sleep Center | Atlanta | Georgia | 30329 | United States |
12 patients were enrolled; of these, 2 were excluded prior to randomization because screening laboratory test results were abnormal.
Participants were recruited from the Sleep Center of the Emory Clinic, in Atlanta, Georgia, USA, between December 2010 and October 2011.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo First, Then Flumazenil | Placebo administered sublingually three times during the first study day, followed by a washout of at least 7 days, then flumazenil administered sublingually three times during the second study day. |
| FG001 | Flumazenil First, Then Placebo | Flumazenil administered sublingually three times during the first study day (as 12 mg, then 6 mg, then 6 mg, at approximately 3 hour intervals), followed by a washout of at least 7 days, then placebo administered sublingually three times on the second study day. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First Intervention Day |
| |||||||||||||
| Washout Period of at Least 1 Week |
| |||||||||||||
| Second Intervention Day |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo First, Then Flumazenil | Placebo during the first intervention day and sublingual flumazenil during the second intervention day (after washout period). |
| BG001 | Flumazenil First, Then Placebo |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Psychomotor Vigilance Task (PVT) Median Reaction Time | The PVT measures the reaction time to button press following the presentation of a visual stimulus, reported here as the median reaction time for multiple presentations during the 10 minute task. The measure used was the change in median reaction time from baseline to drug administration, where the median reaction time at each of the time points (below) was averaged to provide a single on-treatment value for median reaction time. The measure was then calculated as baseline value - treatment value, such that higher numbers denote improvement from baseline. | Intention to treat (all randomized subjects were included) | Posted | Mean | Standard Deviation | msec | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) |
|
Symptoms experienced within 24 hours of drug administration
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| feeling "dizzy", "lightheaded", or "spacey" | Nervous system disorders |
EEG power was specified as a secondary outcome measure. Second-by-second manual artifact removal has been necessary to ensure interpretable data. This artifact removal is in progress and results will be reported separately.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Lynn Marie Trotti | Emory University School of Medicine | 404-728-4752 | lbecke2@emory.edu |
Not provided
| ID | Term |
|---|---|
| D006970 | Disorders of Excessive Somnolence |
| D020177 | Idiopathic Hypersomnia |
| ID | Term |
|---|---|
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D005442 | Flumazenil |
| ID | Term |
|---|---|
| D001570 | Benzodiazepinones |
| D001569 | Benzodiazepines |
| D001552 | Benzazepines |
| D006574 | Heterocyclic Compounds, 2-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) |
| PVT Additional Measure #2, Change in Duration of Lapse Domain | The PVT duration of lapse domain is defined as the reciprocal of the reaction time averaged across the slowest 10% of responses. The measure used was the change in duration of lapse domain from baseline to drug administration (calculated as baseline value - average value with study drug, where lower numbers denote improvement from baseline). | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) |
| PVT Additional Measure #3, Change in Optimum Response Times | The optimum response times is defined as the reciprocal of the reaction time averaged across the fastest 10% of responses. The measure used was the change in optimum response time from baseline to following drug administration (calculated as baseline value - average value with study drug, where lower numbers denote improvement from baseline). | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) |
| PVT Additional Measure #4, Change in False Response Frequency | The false response frequency is defined as the number of button presses when no stimulus is presented. The measure used was the change in false response frequency from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) |
| PVT Additional Measure #5, Change in Visual Analog Scale Rating of Sleepiness at the Completion of PVT | At the end of the 10 minute PVT testing period, subjects were asked to rate their current level of sleepiness along a line, which was transformed into a numeric value from 1-10, such that high levels indicated more severe subjective sleepiness. The measure used was the change in this rating from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) |
| Change in Stanford Sleepiness Scale | The Stanford Sleepiness Scale (SSS) is a subjective rating of sleepiness, with score ranging from 1 to 7, where higher values reflect more severe sleepiness. The measure used was change in SSS from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) |
| Electroencephalogram (EEG) Power | EEG signals reflect the state of excitability of the cerebral cortex and correlate highly with levels of behavioral arousal. This is quantifiable as 'power' of the signal (microvolts squared/signal frequency). The EEG signals will be acquired and stored for off-line power analysis and comparison between treatment conditions. | following drug administration |
| NOT COMPLETED |
|
| NOT COMPLETED |
|
Sublingual flumazenil during the first intervention day and placebo during the second intervention day (after washout period).
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG001 | Sublingual Flumazenil | Sublingual flumazenil administered three times over a single day (12 mg, 6 mg, 6 mg dosing), in either the first or second intervention period |
|
|
|
| Secondary | PVT Additional Measure #1, Change in Lapse Frequency | A PVT lapse is defined as a reaction time exceeding 500 msec following the presentation of a single stimulus, which are then summed for the entire 10 minute PVT testing period. The measure used was the change in the frequency of lapses from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). | Intention to treat (all randomized subjects were included) | Posted | Mean | Standard Deviation | number of lapses during PVT testing | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) |
|
|
|
|
| Secondary | PVT Additional Measure #2, Change in Duration of Lapse Domain | The PVT duration of lapse domain is defined as the reciprocal of the reaction time averaged across the slowest 10% of responses. The measure used was the change in duration of lapse domain from baseline to drug administration (calculated as baseline value - average value with study drug, where lower numbers denote improvement from baseline). | Intention to treat (all randomized subjects were included) | Posted | Mean | Standard Deviation | 1/msec | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) |
|
|
|
|
| Secondary | PVT Additional Measure #3, Change in Optimum Response Times | The optimum response times is defined as the reciprocal of the reaction time averaged across the fastest 10% of responses. The measure used was the change in optimum response time from baseline to following drug administration (calculated as baseline value - average value with study drug, where lower numbers denote improvement from baseline). | Intention to treat (all randomized subjects were included) | Posted | Mean | Standard Deviation | 1/msec | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) |
|
|
|
|
| Secondary | PVT Additional Measure #4, Change in False Response Frequency | The false response frequency is defined as the number of button presses when no stimulus is presented. The measure used was the change in false response frequency from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). | Intention to treat (all randomized subjects were included) | Posted | Mean | Standard Deviation | number of false starts | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) |
|
|
|
|
| Secondary | PVT Additional Measure #5, Change in Visual Analog Scale Rating of Sleepiness at the Completion of PVT | At the end of the 10 minute PVT testing period, subjects were asked to rate their current level of sleepiness along a line, which was transformed into a numeric value from 1-10, such that high levels indicated more severe subjective sleepiness. The measure used was the change in this rating from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). | Intention to treat (all randomized subjects were included) | Posted | Mean | Standard Deviation | units on a scale | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) |
|
|
|
|
| Secondary | Change in Stanford Sleepiness Scale | The Stanford Sleepiness Scale (SSS) is a subjective rating of sleepiness, with score ranging from 1 to 7, where higher values reflect more severe sleepiness. The measure used was change in SSS from baseline to drug administration (calculated as baseline value - average value with study drug, where higher numbers denote improvement from baseline). | Intention to treat (all randomized subjects were included) | Posted | Mean | Standard Deviation | units on a scale | 10, 30, 60, 90, 120, and 150 minutes after drug administration (averaged for all time points for each subject) |
|
|
|
|
| Secondary | Electroencephalogram (EEG) Power | EEG signals reflect the state of excitability of the cerebral cortex and correlate highly with levels of behavioral arousal. This is quantifiable as 'power' of the signal (microvolts squared/signal frequency). The EEG signals will be acquired and stored for off-line power analysis and comparison between treatment conditions. | EEG signal processing analyses have not been performed. This would require an additional set of extensive analyses, very distinct from the statistics performed for the other study outcomes. EEG data were collected for possible future analyses, pending resources and expertise, and as such we have no data to report here. | Posted | following drug administration |
|
|
| 0 |
| 10 |
| 4 |
| 10 |
| EG001 | Sublingual Flumazenil | 0 | 10 | 9 | 10 |
| headache (during or following drug administration) | Nervous system disorders |
|
| feeling "jittery" | Nervous system disorders |
|
| feeling of "panic", "anxiety", or "uneasy" | Psychiatric disorders |
|
| back pain | Musculoskeletal and connective tissue disorders |
|
| feeling "giggly" or "high" | Psychiatric disorders |
|
| feeling dysphoria or "drugged" | Psychiatric disorders |
|
Not provided
Not provided
Not provided
| D001523 |
| Mental Disorders |
| D000072471 |
| Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |